By Dave Sebastian
Eli Lilly & Co. (LLY) said it has struck an agreement with DexCom to use Dexcom products in Lilly's currently developed personalized diabetes management system.
Under the non-exclusive agreement, Lilly said Monday it would use Dexcom's continuous glucose monitoring devices in both the pen- and pump-based platforms of the system.
The pen-based platform aims to integrate personalized data from a prefiled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application, Lilly said.
Lilly said the pump-based platform is a hybrid-closed-loop system that would automate insulin dosing by integrating an insulin pump, continuous glucose monitor and a handheld controller or smartphone application that controls the system.
Write to Dave Sebastian at firstname.lastname@example.org